Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + S1 + albumin paclitaxel
- Development stage
- Preclinical
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of toripalimab (an anti-PD-1 monoclonal antibody), S1 (an oral fluoropyrimidine anticancer agent), and albumin-bound paclitaxel (nab-paclitaxel, a solvent-free formulation of paclitaxel). This regimen combines immunotherapy with chemotherapy to potentially enhance antitumor activity. Toripalimab binds to the PD-1 receptor with high affinity, inducing endocytosis and reducing PD-1 expression on cell membranes. Albumin-bound paclitaxel utilizes albumin as a natural carrier to improve tumor targeting and reduce toxicity compared to conventional paclitaxel. S1 is an oral fluoropyrimidine that combines tegafur with modulators.
- Brand names
- TuoyiAbraxaneTeysuno
- Other names
- nab-paclitaxelTegafur-gimeracil-oteracilTS-1TS1TS 1
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)
Beyond the preview
Go deeper on toripalimab + S1 + albumin paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + S1 + albumin paclitaxel.